Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA Background: Osimertinib has been shown to be superior to erlotinib or gefitinib in previously untreated patients with EGFR mutant (exon 19 deletion/L858R) NSCLC. Osimertinib is approved for the treatment of patients with metastatic T790Mþ NSCLC who have disease progression after EGFR-TKI therapy. The majority of EGFR mutant NSCLC patients who are treated with a TKI ultimately acquire resistance, including those treated with osimertinib. We have recently completed a phase 2 randomized clinical trial demonstrating that patients with oligometastatic NSCLC treated with aggressive local consolidation therapy (surgery or radiation) have improved progression-free survival compared to those patients treated with systemic therapy alone (Gomez et al., Lancet Oncol, 2016) . A retrospective review of EGFR-mutant subset of patients enrolled in the trial suggests that EGFR-mutant patients may derive greater benefit from this approach. Thus, two premises underlie the current randomized trial: 1) osimertinib is standard of care for treatment of primary and TKI resistant EGFR-mutant metastatic NSCLC, and 2) the majority of patients treated with osimertinib ultimately become resistant, and LCT has been found to improve outcomes compared to systemic therapy alone. Trial design: A phase 2 randomized, multicenter, study to evaluate the efficacy of osimertinib with or without LCT for patients with EGFR-mutant metastatic NSCLC. Eligible patients include 1) Previously untreated patients with EGFR-mutant NSCLC (L858R or exon 19 deletion) or 2) NSCLC patients with acquired EGFR T790M that was acquired following progression on first or second generation TKI, this subset of patients must have not received prior third generation TKI. Patients who don't have disease progression after 6-12 weeks of induction osimertinib will be randomized 1:1 to osimertinib continuation or to osimertinib continuation with LCT Primary end point is progression free survival Exploratory biomarkers associated with resistance to osimertinib will be evaluated in tumor tissue and plasma collected at baseline and progression. 140 patients will be enrolled in 5 centers in North America. Clinical trial identification: NCT03410043. Legal entity responsible for the study: UT MD Anderson Cancer Center. Funding: National Comprehensive Cancer Network NCCN, AZ grant. Disclosure: All authors have declared no conflicts of interest.
1510TiP The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors Background: TO (CetuGEX) is a second-generation anti-EGFR antibody that specifically binds to EGFR and acts as a competitive antagonist at the ligand binding site. GAT (PankoMab-GEX) is a novel humanized monoclonal antibody, which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1) expressed on tumor cells. Both antibodies are glyco-engineered to potentiate antibody-dependent cellular cytotoxicity (ADCC). Compelling preclinical evidence suggests a complex interaction between EGFR and cell surface expressed TA-MUC1 in driving neoplastic processes and shows a synergistic antibody dependent cell cytotoxicity activity with the dual targeting of these molecules. Based on this evidence, this study aims to assess the tolerability, safety and preliminary activity of a combination with anti-EGFR and anti-TA-MUC1 glyco-engineered antibodies.
Trial design: The GATTO is an open label phase Ib dose evaluation study in patients with EGFR positive metastatic solid tumors, for whom no standard treatment is available. The proposed doses and schedule are 1200 mg Q2W for TO and 1400 mg Q2W for GAT. A staggered approach will be utilized in order to minimize the number of patients exposed and to evaluate the safety of the combination treatment. The first 6 patients will be enrolled into a safety run-in phase where the number of dose-limiting toxicities (DLTs) will be evaluated. Assuming that the safety criteria are met (ie. observation of 0 or 1 DLT), the dose will remain unchanged and further patients will be recruited at the highest dose level. If this is not the case, a step-wise dose reduction approach will be applied. The antitumor activity of the combined treatment will be evaluated as secondary endpoints including best overall response rate (ORR), duration of objective response (DOR), progression-free (PFS) and overall (OS) survival. Extensive pharmacokinetics (PK) and pharmacodynamics (PD) (cellular immune status, serum and tissue biomarkers) will be also analyzed. As of the beginning of May 2018 the study is ongoing and 6 patients are being treated. 
